Minerva Neurosciences, Inc.
NASDAQ:NERVBiotechnology
-$0.30 today
- Market cap
- $108.64M
- Beta
- -0.11
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.46
Volume 0.28M
Average 0.21M
NERV Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Minerva Neurosciences, Inc.NASDAQ: NERV
Net Margin · Q2 FY2026 · quarter ended Jun 2026
Net margin not reported for Q2 FY2026
Sources:Income StatementText generated from reported figures; not investment advice.
Net Margin history
Percent of revenue · from the income statement
No Net Margin data reported for this period type.
Net Margin vs competitors
How NERV compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
NRXSNeurAxis, Inc. | LTM Mar 2026 | -170.1% | +116.1 pp | -40.5 pp |
| LTM Mar 2026 | -911.1% | +4771.1 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding NERV) | -540.6% | +2443.6 pp | -40.5 pp | |
Competitors are the stored peer set for NERV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.04M | 14.65M | 12.71M | 11.9M | 5.76M |
| Selling, General & Admin | 13.33M | 10.58M | 10.41M | 9.95M | 9.34M |
| Operating Expenses | 45.37M | 25.23M | 23.12M | 21.85M | 15.1M |
| Depreciation & Amortization | 101.79K | 8.51K | 30.98K | 22.47K | 5.44K |
| EBITDA | (45.28M) | (24.69M) | (21.69M) | 6.02M | (293.42M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (45.37M) | (25.23M) | (23.12M) | (21.85M) | (15.1M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 16.52K | 556.95K | 1.44M | 1.27M | 948.12K |
| Interest Expense | 6.33M | 7.41M | 8.28M | 4.56M | 0 |
| Other Income / Expenses | (6.34M) | (6.88M) | (6.89M) | 23.29M | (278.32M) |
| Income Before Tax | (51.71M) | (32.11M) | (30.01M) | 1.44M | (293.42M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (1.8M) | 0 | 0 | 0 | 0 |
| Net Income | (49.91M) | (32.11M) | (30.01M) | 1.44M | (293.42M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (9.35) | (6.01) | (4.61) | 0.19 | (34.67) |
| EPS (Diluted) | (9.35) | (6.01) | (4.61) | 0.19 | (34.67) |
| Weighted Avg Shares | 5.34M | 5.34M | 6.51M | 7.57M | 8.46M |
| Weighted Avg Shares (Diluted) | 5.34M | 5.34M | 6.51M | 7.57M | 8.46M |
Minerva Neurosciences, Inc.
NASDAQ:NERV
Intrinsic Alpha fair value
Locked
Current Price
$2.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.